New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
04:55 EDTSIAL, SIAL, SIAL, MMS, MMS, MMS, MD, MD, MD, MASI, MASI, MASI, LPNT, LPNT, LPNT, STE, STE, STE, XRAY, XRAY, XRAY, MRK, MRK, MRK, JNJ, JNJ, JNJCitigroup to host a conference
Global Healthcare Conference is being held in New York on February 24-26.
News For SIAL;MMS;MD;MASI;LPNT;STE;XRAY;MRK;JNJ From The Last 14 Days
Check below for free stories on SIAL;MMS;MD;MASI;LPNT;STE;XRAY;MRK;JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 15, 2014
07:27 EDTJNJIBC Life Sciences to hold a conference
Subscribe for More Information
September 12, 2014
10:00 EDTLPNTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:23 EDTLPNTLifePoint Hospitals initiated with a Market Perform at Leerink
Target $85.
September 11, 2014
07:11 EDTJNJMedivation price target raised to $112 from $89 at Stifel
Subscribe for More Information
September 10, 2014
16:00 EDTMRKOptions Update; September 10, 2014
Subscribe for More Information
10:14 EDTJNJJohnson & Johnson says off to 'very good start' this year
Subscribe for More Information
September 9, 2014
12:14 EDTLPNTHospitals rise after analyst says positive trends continuing
Subscribe for More Information
07:37 EDTLPNTDeutsche Bank ups price targets in Hospital space
Subscribe for More Information
September 8, 2014
16:00 EDTMRKOptions Update; September 8, 2014
Subscribe for More Information
September 5, 2014
16:45 EDTMRKMarket ends week little changed after mixed economic data
Subscribe for More Information
11:17 EDTMRKBristol-Myers files patent infringement suit against Merck
Subscribe for More Information
10:05 EDTJNJOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) initiated with a Buy at ISI Group... Akamai (AKAM) initiated with a Buy at UBS... Alexion (ALXN) initiated with a Buy at SunTrust... Allegion (ALLE) initiated with a Buy at Buckingham... Allergan (AGN) initiated with a Buy at ISI Group... Aviat Networks (AVNW) initiated with a Neutral at H.C. Wainwright... Celgene (CELG) initiated with a Buy at SunTrust... EZCORP (EZPW) initiated with a Hold at Jefferies... Eaton (ETN) initiated with a Neutral at Buckingham... Emerson (EMR) initiated with a Neutral at Buckingham... HMS Holdings (HMSY) initiated with an Overweight at Stephens... Incyte (INCY) initiated with a Buy at SunTrust... Ingersoll-Rand (IR) initiated with a Neutral at Buckingham... Insmed (INSM) initiated with an Outperform at Cowen... Intercept (ICPT) initiated with an Outperform at Cowen... Johnson & Johnson (JNJ) initiated with an Outperform at BMO Capital... Lennox (LII) initiated with a Neutral at Buckingham... Mylan (MYL) initiated with a Hold at ISI Group... Orion Engineered Carbons (OEC) initiated with a Buy at Goldman... Parker-Hannifin (PH) initiated with a Buy at Buckingham... Pentair (PNR) initiated with a Neutral at Buckingham... Pharmacyclics (PCYC) initiated with a Neutral at SunTrust... Rockwell Automation (ROK) initiated with a Neutral at Buckingham... Sabre (SABR) initiated with an Outperform at Oppenheimer... Santander Consumer (SC) initiated with a Buy at Jefferies... Springleaf (LEAF) initiated with a Buy at Jefferies... Susser Petroleum (SUSP) initiated with a Neutral at Credit Suisse... Teva (TEVA) initiated with a Buy at ISI Group... Valeant (VRX) initiated with a Buy at ISI Group... WESCO (WCC) initiated with a Neutral at Buckingham... Watsco (WSO) initiated with a Neutral at Buckingham... Weyerhaeuser (WY) initiated with a Neutral at JPMorgan... World Acceptance (WRLD) initiated with a Hold at Jefferies.
08:41 EDTJNJJohnson & Johnson initiated with an Outperform at BMO Capital
Target $118.
08:39 EDTMRKMerck Keytruda sales to reach $5B in 2018, says BMO Capital
Subscribe for More Information
07:01 EDTMDMEDNAX completes acquisition of MedData
MEDNAX announced that it has completed the previously disclosed acquisition of MedData, a provider of revenue cycle management services that offers professional and facility coding, billing and collections, as well as an industry leading early out/patient pay solution to emergency department, hospitalist, physician specialty groups and hospitals. This was a cash transaction and is expected to be accretive to earnings, after non-cash amortization expense and interest expense.
September 4, 2014
15:16 EDTMRKMerck receives accelerated approval of Keytruda
Subscribe for More Information
11:05 EDTJNJJ&J unit Janssen receives orphan status for whipworm treatment
Subscribe for More Information
09:02 EDTMRKMerck's relebactam granted QIDP, fast track designations by FDA
Merck announced that the U.S. Food and Drug Administration has designated relebactam -- previously known as MK-7655 -- the company’s investigational beta-lactamase inhibitor, as a Qualified Infectious Disease Product with designated Fast Track status. The QIDP and Fast Track designations apply to intravenous use of relebactam for the treatment of complicated urinary tract infections, complicated intra-abdominal infections and hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. Relebactam is an investigational, class A and C, beta-lactamase inhibitor that is being evaluated in combination with imipenem/cilastatin in ongoing Phase 2 clinical trials for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. In preclinical studies, relebactam administered in combination with imipenem/cilastatin demonstrated antibacterial activity against a broad range of Gram-negative and beta-lactam-resistant pathogens. Merck plans to initiate Phase 3 studies with relebactam in combination with imipenem/cilastatin in 2015.
07:21 EDTMRKMedidata can obtain major new platform customers, says Stifel
Noting that Medidata (MDSO) partners with Veeva, Stifel believes that a number of Veeva (VEEV) customers could become Medidata platform customers, especially if they already use Medidata for R&D and clinical trial solutions. The firm identifies Merck (MRK), Gilead (GILD), and Teva (TEVA) as companies that may become platform clients for Medidata. Stifel keeps a $55 price target and Buy rating on Medidata.
05:23 EDTJNJJohnson & Johnson to fast-track development of Ebola combination vaccine regimen
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use